Dr. Eileen O’Meara is a Professor at the Department of Medicine at the Université de Montréal and practices cardiology at the Montreal Heart Institute. She pursued a Fellowship in Heart Failure at the Western Infirmary & Glasgow Royal Infirmary in the UK, and another in Stress Echocardiography and Tissue Doppler at Hôpital Européen Georges Pompidou in Paris. From 2007 to 2010, Dr. O’Meara oversaw resident training/teaching at the Montreal Heart Institute’s Echocardiography Laboratory. She is a member of the Research Core Echocardiography Laboratory at MHI and a member of the teaching Committee at Université de Montréal for Multisystem Diseases. She is currently in charge of the Physiology program organization for students in nutrition and rehabilitation at U de M.
She is a member of the Internal Review Board for Research at the Montreal Heart Institute and, in 2018, she became the Chief of Outpatients Clinics at MHI. Dr. O’Meara is a Fellow of the Royal College of Physicians of Canada and a member of multiple cardiology associations. She was Co-Chair of the Primary Panel for the Canadian Cardiovascular Society and Canadian Heart Failure Society (CCS and CHFS) Heart Failure Guidelines (2016-2019) and is currently co-chair of the Cardiorenal Protection with Anti-Hyperglycemic Agents Guidelines for the CCS/CHFS (2020-2022). She is a member of the Editorial Board for Circulation: Heart Failure and serves as a Reviewer for the Canadian Journal of Cardiology, the European Heart Journal, the European Journal of Heart Failure, Circulation and Circulation: Heart Failure, and the Journal of Cardiac Failure, among others, and does abstract grading for the European Society of Cardiology and CCC meetings.
Her research focuses on remodeling and fibrosis biomarkers in HF, including cardiac imaging biomarkers; as well as on comorbid conditions that contribute to HF, more specifically diabetes, CKD, and anemia. Dr. O’Meara has long been involved in clinical research on HF with preserved ejection fraction (HFpEF) and was the Canadian lead investigator for the TOPCAT and PARAGON-HF trials and is currently co-national lead investigator for the DELIVER trial. For HF with reduced ejection fraction, she was the national lead investigator for the DAPA-HF and the GALACTIC trials; as well as a member of the Steering Committees for the GALACTIC-HF trial and, currently, for the HEART-FID trial (IV iron vs. placebo in HFrEF with regards to major clinical outcomes).